|Videos|January 4, 2023

Addressing RSV in the Pediatric Population

One clinician offers some insights on the RSV surge witnessed last year and the prospective benefits of having a maternal vaccine to protect newborns from this virus.


The reemergence of respiratory syncytial virus (RSV) last year and its timing has been puzzling to clinicians and public health officials. There have been reports going back to last summer with pediatric patients being diagnosed and hospitalized with the virus, and certainly this past fall, a surge in RSV overwhelmed hospitals and the health care system in some areas of the US— which was out of the norm for this seasonal virus.

The Centers for Disease Control and Prevention (CDC) has noted on their website the increased incidence rates. “CDC surveillance has shown an increase in RSV detections and RSV-associated emergency department visits and hospitalizations in multiple US regions, with some regions nearing seasonal peak levels. Clinicians and public health professionals should be aware of increases in respiratory viruses, including RSV.”

And although the exact cause has not been defined, some point to the COVID-19 pandemic disrupting the typical seasonal cycle of viruses.

“The pandemic really did change the pattern with which the respiratory viruses circulate,” Tina Q. Tan, MD, professor of Pediatrics at the Feinberg School of Medicine, Northwestern University, and a pediatric infectious diseases physician at the Ann & Robert H. Lurie Children’s Hospital, Chicago, Illinois. “We don’t really understand why that occurred, but we do know RSV, influenza, and even COVID [and that] these surges are occurring much earlier than they normally would.”

This along with the rise of other viruses has made diagnosis difficult, Tan explains. The surge in these viruses has impacted treatment and created shortages of Albuterol and antibiotics. “The problem is that when some of these kids and infants present to an emergency room that is not pediatric or to an urgent care many [providers] will take a look at them and think, ‘will they develop a bacterial infection?’ And this has really led to the shortage of antibiotics because these kids are being placed on antibiotics unnecessarily.”

Contagion spoke to Tan about these existing RSV issues, including systemic changes, and the potential of RSV vaccines that could help address the pediatric population and infants.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.